Free Newsletter
Prepare for a fight on DTC tax breaks
Free newsletter via e-mail
Tools
It had to happen: Big Pharma's tax deduction for DTC ads has entered the health-reform debate. Rep. Charles Rangel, chair of House Ways and Means, says Congress could yank that tax break to help raise $37 billion toward reform costs. We all knew this was up for grabs; even before President Obama took office, his people had raised the idea.
As the press points out today, however, pharma spends around $4.7 billion on advertising annually. So wherefore $37 billion? Does it encompass pharma's entire sales, general and admin budget, as BNet Pharma and Ad Age suggest? Or is it an accumulated-over-time savings figure (eight years times $4 billion and change could equal $37 billion, if you squint)?
That's just one of the big questions surrounding Rangel's proposal; another biggie is this: Why would it be OK for other industries to get tax deductions for advertising expenses, but not pharma? The answer might be that, like cigarettes and alcohol, pharma advertising already is treated differently from your garden variety consumer ads. After all, the U.S. is one of the very few countries worldwide to allow DTC promotions, and here it's only been allowed since 1981.
Still, the drug industry and ad industry have their side of that story; already, some are predicting First Amendment challenges to Rangel's proposal, if passed. BNet suggests that pharma use the tax deduction as a bargaining chip for some aspect of reform in its favor. What do you think?
- read the BNet post
- check out the Ad Age story
Related Articles:
Could pharma lose DTC tax deduction?
Pharma cuts 2008 ad budgets
Big Pharma's Top 13 Advertising Budgets
Drugmakers to delay new-drug ads
Pharma racks up multibillion-dollar marketing bill (2007)
Comments
By H Rutner | Posted 1:55pm | June 18, 2009
Yanking the DTC break of $37 billion is totally justified in light of a mere $4.7 billion in actual ad expenses. The rest is just cost padding, hence a foolish handout to an industry that routinely posts profits of 20+%, far higher than in most other sectors, even while claiming huge losses from failed clinical trials due to errors in judgment. It's high time to have the coddled and greedy big pharmas pay their fair share of the tax burden, while they extort exorbitant dollar amounts from Rx sales to domestic seniors living largely on fixed incomes!
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
